See every side of every news story

Published 1 day ago • loading... • Updated 1 day ago

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

Summary by KTEN

Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels

35 Articles

35 Articles

Beatrice Daily Sun

+34 Reposted by 34 other sources

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources35

Leaning Left1Leaning Right3Center19Last Updated8 hours agoBias Distribution

83% Center

Bias Distribution

83% of the sources are Center

83% Center

+14

Untracked bias

+3

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States 1 day ago on Monday, June 1, 2026.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics